{"id":"W3029082024","doi":"10.1200/jco.2020.38.15_suppl.tps3160","title":"A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Nap; Medicine; Immunotherapy; Antigen; Cancer research; Immune system; Immune checkpoint; Oncology; Immunology; Nivolumab; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000877809,0.001662205,0.001307951,0.0004145826,0.0004456244,0.0007959028,0.0009613878,0.001310095,0.00594032],"category_scores_gemma":[0.0004840878,0.0004748744,0.0008446939,0.0003148879,0.0008164459,0.001057134,0.0003078411,0.003210846,0.001430699],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001031638,"about_ca_system_score_gemma":0.001097288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001058139,"about_ca_topic_score_gemma":0.003129708,"domain_scores_codex":[0.9997622,0.00007565826,0.000009582208,0.00004705368,0.00002619321,0.00007935188],"domain_scores_gemma":[0.9996107,0.00004381885,0.00006890912,0.00002991151,0.00001899283,0.0002277451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7035984,0.109653,0.004452566,0.001059013,0.001039019,0.0004571309,0.0003790981,0.002554482,0.06350032,0.0005269169,0.007660472,0.1051195],"study_design_scores_gemma":[0.4962803,0.4795278,0.01119694,0.00004205918,0.0003371597,0.000386403,0.00008274985,0.001243537,0.004976299,0.0004135593,0.005484854,0.00002841289],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866895,0.002117746,0.0006510069,0.0007515011,0.0002032409,0.00377974,0.002415974,0.0001440886,0.003247194],"genre_scores_gemma":[0.9817139,0.001955273,0.001489654,0.001194285,0.0001545336,0.003823379,0.003833946,0.00002909028,0.005806034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00594032,"threshold_uncertainty_score":0.01987237,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1893348622942087,"score_gpt":0.5145610612842015,"score_spread":0.3252261989899928,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}